





Appendix 7, as supplied by the authors. Appendix to: Yau K, Chan CT, Abe KT, et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. *CMAJ* 2022. doi: 10.1503/cmaj.211881. Copyright © 2022 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.



Observations

C)

Appendix 7, as supplied by the authors. Appendix to: Yau K, Chan CT, Abe KT, et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. *CMAJ* 2022. doi: 10.1503/cmaj.211881. Copyright © 2022 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.



Observations

Appendix 7, as supplied by the authors. Appendix to: Yau K, Chan CT, Abe KT, et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. *CMAJ* 2022. doi: 10.1503/cmaj.211881. Copyright © 2022 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

Supplementary Appendix 7: Standardized weighted residuals in multivariable β -regression models versus number of observations for (A) anti-Spike at 6-7 weeks (B) anti-RBD at 6-7 weeks (C) anti-Spike at 12 weeks, and (D) anti-RBD at 12 weeks.

Appendix 7, as supplied by the authors. Appendix to: Yau K, Chan CT, Abe KT, et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. *CMAJ* 2022. doi: 10.1503/cmaj.211881. Copyright © 2022 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.